A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 12 Sep 2018 to 30 Oct 2018.
- 30 Jul 2018 New trial record